DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

[1]  Ron A M Fouchier,et al.  Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans , 2009, Science.

[2]  Shixia Wang,et al.  Influenza H5 Hemagglutinin DNA Primes the Antibody Response Elicited by the Live Attenuated Influenza A/Vietnam/1203/2004 Vaccine in Ferrets , 2011, PloS one.

[3]  Chih-Jen Wei,et al.  Cross-Neutralization of 1918 and 2009 Influenza Viruses: Role of Glycans in Viral Evolution and Vaccine Design , 2010, Science Translational Medicine.

[4]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[5]  A. Charlett,et al.  Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. , 2004, Virus research.

[6]  K. Subbarao,et al.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. , 2010, The Journal of clinical investigation.

[7]  Surender Khurana,et al.  Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin , 2011, Proceedings of the National Academy of Sciences.

[8]  Amanda Balish,et al.  Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. , 2009, The New England journal of medicine.

[9]  R. Belshe,et al.  The origins of pandemic influenza--lessons from the 1918 virus. , 2005, The New England journal of medicine.

[10]  J. Mascola,et al.  A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial , 2008, Vaccine.

[11]  J. Skehel,et al.  Variation and infectivity neutralization in influenza , 2006, Immunology.

[12]  Y. Isegawa,et al.  A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains , 1993, Journal of virology.

[13]  G. Nabel,et al.  Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination , 2010, Science.

[14]  R. Koup,et al.  A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial , 2006, Clinical and Vaccine Immunology.

[15]  A. García-Sastre,et al.  Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. , 2008, Vaccine.

[16]  R. Koup,et al.  Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa , 2010, PloS one.

[17]  N. Khardori,et al.  Triple-Reassortant Swine Influenza A (H1) in Humans in the United States, 2005–2009 , 2009 .

[18]  Yan Li,et al.  Human infection with a triple-reassortant swine influenza A(H1N1) virus containing the hemagglutinin and neuraminidase genes of seasonal influenza virus. , 2010, The Journal of infectious diseases.

[19]  J. Mascola,et al.  A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. , 2011, The Journal of infectious diseases.

[20]  Chih-Jen Wei,et al.  Immunization by Avian H5 Influenza Hemagglutinin Mutants with Altered Receptor Binding Specificity , 2007, Science.

[21]  J. Mascola,et al.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. , 2006, The Journal of infectious diseases.

[22]  G. Nabel,et al.  Enhanced Breadth of CD4 T-Cell Immunity by DNA Prime and Adenovirus Boost Immunization to Human Immunodeficiency Virus Env and Gag Immunogens , 2005, Journal of Virology.

[23]  B. Graham,et al.  DNA vaccines: A safe and efficient platform technology for responding to emerging infectious diseases , 2009, Human vaccines.

[24]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[25]  Mark Wolff,et al.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. , 2006, The New England journal of medicine.

[26]  M. Fay,et al.  A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. , 2007, The Journal of infectious diseases.

[27]  M. Mulligan,et al.  Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. , 2011, The Journal of infectious diseases.

[28]  J. Mascola,et al.  Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. , 2007, Vaccine.

[29]  W. C. Hwang,et al.  Wide Prevalence of Heterosubtypic Broadly Neutralizing Human Anti–Influenza A Antibodies , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  R. Koup,et al.  Safety and Immunogenicity of a Gag-Pol Candidate HIV-1 DNA Vaccine Administered by a Needle-Free Device in HIV-1-Seronegative Subjects , 2007, Journal of acquired immune deficiency syndromes.

[31]  M. Hoelscher,et al.  A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). , 2010, The Journal of infectious diseases.

[32]  John Steel,et al.  Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies , 2008, Proceedings of the National Academy of Sciences.

[33]  J. Mascola,et al.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. , 2006, The Journal of infectious diseases.

[34]  C W Potter,et al.  Determinants of immunity to influenza infection in man. , 1979, British medical bulletin.